{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:36:28Z","timestamp":1792708588538,"version":"4.5.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Generalized pustular psoriasis (GPP) is a potentially life-threatening rare immune-mediated disease characterized by rapid onset of erythematous plaques, sterile pustules and systemic inflammation. Spesolimab, a monoclonal antibody targeting the interleukin-36 receptor, is a novel treatment for GPP. However, GPP\u2019s low incidence and limited evidence relating to treatment with spesolimab represents a challenge in determining its real-world efficacy. This review explores the clinical use of spesolimab in a real-world setting. We conducted a review on PubMed, SCOPUS, Embase, and ScienceDirect of case series and reports of patients with GPP treated with spesolimab. Review articles and clinical trials were excluded. From 33 articles, 62 patients with GPP were included. Age ranged from 4 to 88\u2005years. Comorbidities were reported in 48 of the 62 patients; of these, 30 had plaque psoriasis. Spesolimab 900\u2005mg intravenous was administered in one to four doses, depending on clinical response. The second dose was administered 1 week after the first, while the additional doses were given at variable intervals. Follow-up periods ranged from 2 weeks to 15\u2005months. Complete GPP remission was observed in 35\/62 (56%) patients, 21 of them achieving it within a week. Partial remission was defined in 27 of the 62 patients (44%). GPP recurrence after treatment was observed in seven patients. Among the 30 patients with concomitant plaque psoriasis reported, after spesolimab administration, plaque psoriasis recurrence was reported in 6 (20%) patients, 3 (10%) reported improvement and for 21 (70%), this outcome was not reported. Eight patients reported adverse effects, including laboratory abnormalities, infections and erythema multiforme. Spesolimab demonstrates a low prevalence of adverse events and clinical efficacy for GPP treatment, including in patients with comorbidities, infections and those &amp;gt; 75\u2005years of age. Its effect on plaque psoriasis remains unclear.<\/jats:p>","DOI":"10.1093\/ced\/llaf238","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:05:52Z","timestamp":1748581552000},"page":"1733-1740","source":"Crossref","is-referenced-by-count":3,"title":["Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5099-0079","authenticated-orcid":false,"given":"Jesus Alberto","family":"Cardenas-de la Garza","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University Hospital \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Autonoma de Nuevo Leon , Monterrey ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5789-7774","authenticated-orcid":false,"given":"Emmanuel","family":"Dominguez-Chapa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Autonoma de Nuevo Leon , Monterrey ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2281-9451","authenticated-orcid":false,"given":"Angel Kevin","family":"Garza-Elizondo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Autonoma de Nuevo Leon , Monterrey ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9057-6218","authenticated-orcid":false,"given":"Rebeca L","family":"Polina-Lugo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Autonoma de Nuevo Leon , Monterrey ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3906-5987","authenticated-orcid":false,"given":"Jose Dario","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Autonoma de Nuevo Leon , Monterrey ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3306-0069","authenticated-orcid":false,"given":"Esperanza","family":"Welsh","sequence":"additional","affiliation":[{"name":"Welsh Dermatology and Associates, Monterrey Nuevo Leon ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-7065","authenticated-orcid":false,"given":"Minerva","family":"G\u00f3mez-Flores","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Autonoma de Nuevo Leon , Monterrey ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-2109","authenticated-orcid":false,"given":"Dionicio A","family":"Galarza-Delgado","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Autonoma de Nuevo Leon , Monterrey ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025082212470898000_llaf238-B1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.abd.2021.05.011","article-title":"Generalized pustular psoriasis (von Zumbusch)","volume":"97","author":"Romiti","year":"2022","journal-title":"An Bras Dermatol"},{"key":"2025082212470898000_llaf238-B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40265-023-01988-0","article-title":"Spesolimab for the treatment of generalized pustular psoriasis","volume":"84","author":"Bernardo","year":"2024","journal-title":"Drugs"},{"key":"2025082212470898000_llaf238-B3","doi-asserted-by":"crossref","first-page":"1035037","DOI":"10.3389\/fgene.2022.1035037","article-title":"Case report: infantile generalized pustular psoriasis with IL36RN and CARD14 gene mutations","volume":"13","author":"Tong","year":"2023","journal-title":"Front Genet"},{"key":"2025082212470898000_llaf238-B4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s13555-022-00881-0","article-title":"Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment","volume":"13","author":"Rivera-D\u00edaz","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025082212470898000_llaf238-B5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/bjd\/ljad158","article-title":"Incidence and prevalence of generalized pustular psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in the Teleprimary Care (TPC\u00ae) clinical information system from 2010 to 2020","volume":"189","author":"Choon","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025082212470898000_llaf238-B6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ad.2022.09.012","article-title":"Epidemiology and geographic distribution of generalized pustular psoriasis in Spain: a national population-based study of hospital admissions from 2016 to 2020","volume":"114","author":"Montero-Vilchez","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"2025082212470898000_llaf238-B7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/jdv.18820","article-title":"Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study","volume":"37","author":"Navarini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470898000_llaf238-B8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J Dermatol"},{"key":"2025082212470898000_llaf238-B9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamadermatol.2024.0915","article-title":"International consensus definition and diagnostic criteria for generalized pustular psoriasis from the International Psoriasis Council","volume":"160","author":"Choon","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2025082212470898000_llaf238-B10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/bjd\/ljad071","article-title":"The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity","volume":"189","author":"Burden","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025082212470898000_llaf238-B11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40265-022-01825-w","article-title":"Spesolimab: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"2025082212470898000_llaf238-B12","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"2025082212470898000_llaf238-B13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"2025082212470898000_llaf238-B14","first-page":"369","article-title":"First experiences in real clinical practice treating a patient with generalised pustular psoriasis with spesolimab","volume":"2","author":"Fernandez-Galvan","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470898000_llaf238-B15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5114\/ada.2023.129514","article-title":"Rapid response of spesolimab in biologics \u2013 failure patient with generalized pustular psoriasis flare","volume":"40","author":"Jiang","year":"2023","journal-title":"Postepy Dermatol Alergol"},{"key":"2025082212470898000_llaf238-B16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00105-023-05140-7","article-title":"Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab","volume":"74","author":"M\u00fcller","year":"2023","journal-title":"Dermatologie (Heidelb)"},{"key":"2025082212470898000_llaf238-B17","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/1346-8138.17014","article-title":"Pneumocystis pneumonia in a patient with severe generalized pustular psoriasis treated with biologics","volume":"51","author":"Noguchi","year":"2024","journal-title":"J Dermatol"},{"key":"2025082212470898000_llaf238-B18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/ced\/llad108","article-title":"Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis","volume":"48","author":"Ran","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2025082212470898000_llaf238-B19","first-page":"1646","article-title":"Generalised pustular psoriasis triggered by monkeypox vaccination successfully treated with spesolimab","volume":"3","author":"Alfonso","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470898000_llaf238-B20","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1111\/jdv.19678","article-title":"Spesolimab in patients with flare of generalized pustular psoriasis: a multicentre case-series","volume":"38","author":"Bellinato","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470898000_llaf238-B21","doi-asserted-by":"crossref","first-page":"2050313X241235451","DOI":"10.1177\/2050313X241235451","article-title":"Generalized pustular psoriasis successfully treated with spesolimab: a case report","volume":"12","author":"Brigenti","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"2025082212470898000_llaf238-B22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/ced\/llad389","article-title":"Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review","volume":"49","author":"Cardenas-de la Garza","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2025082212470898000_llaf238-B23","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.2147\/JIR.S485077","article-title":"Successful treatment of pediatric generalized pustular psoriasis (GPP) with spesolimab: 5 case reports and evaluations of circulating IL-36 levels","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"key":"2025082212470898000_llaf238-B24","first-page":"61","article-title":"Spesolimab for the treatment of generalized pustular psoriasis: real life experience","volume":"159","author":"Dattola","year":"2024","journal-title":"Ital J Dermatol Venerol"},{"key":"2025082212470898000_llaf238-B25","first-page":"266","article-title":"Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab","volume":"82","author":"Gea","year":"2024","journal-title":"Port J Dermatol and Venereol"},{"key":"2025082212470898000_llaf238-B26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jdcr.2024.05.016","article-title":"Generalized pustular psoriasis successfully treated with spesolimab in the setting of metastatic colon cancer","volume":"50","author":"Guy","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2025082212470898000_llaf238-B27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/ds.DS-D-23-00107","article-title":"Treatment responses of four different biologics in a patient with recurrent generalized pustular psoriasis harboring IL36RN mutation","volume":"42","author":"Hsieh","year":"2024","journal-title":"Dermatol Sin"},{"key":"2025082212470898000_llaf238-B28","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1111\/1346-8138.17431","article-title":"Successful treatment with spesolimab for generalized pustular psoriasis in an elderly patient with TRPM4 mutation","volume":"52","author":"Hsieh","year":"2025","journal-title":"J Dermatol"},{"key":"2025082212470898000_llaf238-B29","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/j.amjmed.2024.06.024","article-title":"Generalized pustular psoriasis (von Zumbusch)","volume":"137","author":"Ryosuke","year":"2024","journal-title":"Am J Med"},{"key":"2025082212470898000_llaf238-B30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1684\/ejd.2024.4785","article-title":"Analysis of the German compassionate use program on spesolimab in patients with generalized pustular psoriasis: evidence outside of clinical trials","volume":"34","author":"Krefting","year":"2024","journal-title":"Eur J Dermatol"},{"key":"2025082212470898000_llaf238-B31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.abd.2024.09.003","article-title":"Rapid improvement in a recurrent generalized pustular psoriasis patient ineffective to ixekizumab following spesolimab therapy","volume":"100","author":"Li","year":"2025","journal-title":"An Bras Dermatol"},{"key":"2025082212470898000_llaf238-B32","doi-asserted-by":"crossref","first-page":"110280","DOI":"10.1016\/j.clim.2024.110280","article-title":"Spesolimab rapidly treats generalized pustular psoriasis and improves the skin immune microenvironment in Chinese patients","volume":"265","author":"Lu","year":"2024","journal-title":"Clin Immunol"},{"key":"2025082212470898000_llaf238-B33","first-page":"696","article-title":"Severe flare of generalized pustular psoriasis treated with spesolimab, an IL-36-directed monoclonal antibody","volume":"22","author":"Mateeva","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025082212470898000_llaf238-B34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1346-8138.17032","article-title":"A case of generalized pustular psoriasis with discrepant resolution time between pustules and erythema after treatment with spesolimab","volume":"51","author":"Matsuo","year":"2024","journal-title":"J Dermatol"},{"key":"2025082212470898000_llaf238-B35","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1111\/1346-8138.17243","article-title":"A case of generalized pustular psoriasis complicated with SLE successfully treated with spesolimab","volume":"51","author":"Minami","year":"2024","journal-title":"J Dermatol"},{"key":"2025082212470898000_llaf238-B36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1684\/ejd.2024.4711","article-title":"Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation","volume":"34","author":"Nakajima","year":"2024","journal-title":"Eur J Dermatol"},{"key":"2025082212470898000_llaf238-B37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/1346-8138.17464","article-title":"Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab","volume":"52","author":"Ogawa","year":"2025","journal-title":"J Dermatol"},{"key":"2025082212470898000_llaf238-B38","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/1346-8138.17337","article-title":"Spesolimab improved pustules on the palms and soles that were refractory to tumor necrosis factor inhibitors and interleukin-17 inhibitors in a patient with generalized pustular psoriasis: a case report","volume":"51","author":"Suzuki","year":"2024","journal-title":"J Dermatol"},{"key":"2025082212470898000_llaf238-B39","first-page":"e60331","article-title":"Spesolimab in the management of generalized pustular psoriasis with concurrent bullous pemphigoid and psoriasis","volume":"16","author":"Teshima","year":"2024","journal-title":"Cureus"},{"key":"2025082212470898000_llaf238-B40","first-page":"1679","article-title":"Long-term remission and normal pregnancy with successful delivery in a patient with generalized pustular psoriasis after spesolimab","volume":"12","author":"Wang","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025082212470898000_llaf238-B41","doi-asserted-by":"crossref","first-page":"1338285","DOI":"10.3389\/fimmu.2024.1338285","article-title":"Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report","volume":"15","author":"Wen","year":"2024","journal-title":"Front Immunol"},{"key":"2025082212470898000_llaf238-B42","doi-asserted-by":"crossref","first-page":"2334791","DOI":"10.1080\/09546634.2024.2334791","article-title":"Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab","volume":"35","author":"Yang","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2025082212470898000_llaf238-B43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40257-024-00906-8","article-title":"Real-world experience of spesolimab for generalized pustular psoriasis flares in adult patients: a multicenter retrospective study","volume":"26","author":"Yeung","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"2025082212470898000_llaf238-B44","first-page":"e64474","article-title":"Effective management of life-threatening generalized pustular psoriasis flare with spesolimab","volume":"16","author":"Zafiriou","year":"2024","journal-title":"Cureus"},{"key":"2025082212470898000_llaf238-B45","doi-asserted-by":"crossref","first-page":"adv42368","DOI":"10.2340\/actadv.v105.42368","article-title":"Generalized pustular psoriasis with breast cancer successfully treated with spesolimab causing neutrophilia: a case report","volume":"105","author":"Obata","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"2025082212470898000_llaf238-B46","doi-asserted-by":"crossref","first-page":"adv42177","DOI":"10.2340\/actadv.v105.42177","article-title":"Crusted scabies in a patient being treated with spesolimab for generalized pustular psoriasis","volume":"105","author":"Schratter","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"2025082212470898000_llaf238-B47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaad.2023.09.078","article-title":"Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation","volume":"90","author":"Hackley","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470898000_llaf238-B48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.34172\/hpp.2021.32","article-title":"A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report","volume":"11","author":"Onsun","year":"2021","journal-title":"Health Promot Perspect"},{"key":"2025082212470898000_llaf238-B49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.abd.2023.07.016","article-title":"A case of generalized pustular psoriasis following Moderna\/NIAID COVID-19 vaccination successfully treated with secukinumab","volume":"99","author":"Kusano","year":"2024","journal-title":"An Bras Dermatol"},{"key":"2025082212470898000_llaf238-B50","first-page":"139","article-title":"Comorbidity in adult psoriasis: considerations for the clinician","volume":"12","author":"Daugaard","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"2025082212470898000_llaf238-B51","first-page":"71","article-title":"Comorbidities in psoriasis: the recognition of psoriasis as a systemic disease and current management","volume":"51","author":"Kalkan","year":"2017","journal-title":"Turkderm-Turk Arch Dermatol Venereol"},{"key":"2025082212470898000_llaf238-B52","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/jdv.18720","article-title":"Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review","volume":"37","author":"Prinz","year":"2023","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"2025082212470898000_llaf238-B53","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1002\/ski2.343","article-title":"Targeted review of IL36RN mutations in patients with generalised pustular psoriasis","volume":"4","author":"Krueger","year":"2024","journal-title":"Skin Health Dis"},{"key":"2025082212470898000_llaf238-B54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/actadv.v102.2412","article-title":"Safety assessment of conventional and biological systemic therapy in older adults with psoriasis, a real-world multicentre cohort study","volume":"102","author":"Ter Haar","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025082212470898000_llaf238-B55","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.3390\/jcm12237215","article-title":"Aging Impact in response to different classes of biological treatment in psoriatic patients: a real-life observational study","volume":"12","author":"Rosset","year":"2023","journal-title":"J Clin Med"},{"key":"2025082212470898000_llaf238-B56","first-page":"9","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"11","author":"Mahil","year":"2017","journal-title":"Sci Transl Med"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf238\/63404037\/llaf238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1733\/63404037\/llaf238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1733\/63404037\/llaf238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:47:20Z","timestamp":1755881240000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/9\/1733\/8153554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf238","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,30]]}}}